HC Wainwright & Co. analyst Brandon Folkes has reiterated a Buy rating on Trevi Therapeutics (TRVI) and increased the price target from $21 to $24. This analyst action suggests continued confidence in the company's prospects, potentially leading to positive short-term sentiment for TRVI shares.
HC Wainwright & Co. analyst Brandon Folkes maintained a Buy rating on Trevi Therapeutics and raised the price target from $21 to $24. This action signals increased analyst confidence in the company's future performance and valuation. It primarily affects Trevi Therapeutics, as the updated price target provides a new benchmark for investors and could influence trading decisions. In the short term, this could lead to increased buying interest and a potential uptick in TRVI's stock price. Long-term implications depend on whether the company meets or exceeds the analyst's expectations. A key opportunity for traders is to capitalize on any immediate positive momentum, while the risk lies in the possibility that the market may not fully embrace the new price target or that future company news could negate this positive sentiment.